Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms By Ogkologos - August 6, 2025 397 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SAVANNAH study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Expanding the horizons of the life science economy May 3, 2022 Investing in volunteers since 2002: The tale of time July 11, 2022 New on NCI’s Websites for December 2020 December 31, 2020 Using a Mind-Body Connection to Help You Cope During Cancer: An... January 11, 2024 Load more HOT NEWS Copanlisib Shows Promising Clinical Activity in Select Tumours with PIK3CA Mutation... FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell... Παρακολούθηση και Φροντίδα FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Advanced NSCLC
